Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Exelixis receives $20 million for new anticancer molecule

This article was originally published in Scrip

Executive Summary

Exelixis will receive $20 million in milestones after Bristol-Myers Squibb exercised its option to develop and commercialise Exelixis's XL413, a potential first-in-class anticancer therapy. The late-stage preclinical selective inhibitor of Cdc7, which is thought to play an important role in cancer cells, is thought to be the most clinically advanced inhibitor of its kind. Exelixis will co-develop and co-commercialise XL413 in the US and the two firms will halve profits equally. BMS will be responsible for all non-US activities and Exelixis will receive double-digit royalties on product sales outside the US. XL413 is the second molecule that BMS is taking forward as part of a collaboration the two firms agreed in January 2007 whereby Exelixis identifies preclinical drug candidates against selected targets. This January BMS chose to develop Exelixis's anticancer XL139, an inhibitor of the hedgehog signalling pathway, for which Exelixis also received $20 million.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts